Sonoma Pharmaceuticals (SNOA) P/E Ratio
P/E Ratio as of Mar 10, 2026: -1.28
Average-1.36
Median-1.39
Minimum-1.44
Maximum-1.17
-1.28
0.10 (7.25%)past month
The P/E ratio for Sonoma Pharmaceuticals (SNOA) is -1.28 as of Mar 10, 2026. This represents a decrease of -0.78% compared to its 12-month average P/E ratio of -1.29. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Sonoma Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Sonoma Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Sonoma Pharmaceuticals to industry peers.
Sonoma Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Sonoma Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Sonoma Pharmaceuticals to industry peers.
Sonoma Pharmaceuticals (SNOA) P/E Ratio Insights
See Sonoma Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Sonoma Pharmaceuticals (SNOA)
Order type
Buy in
Order amount
Est. shares
0 shares
Sonoma Pharmaceuticals (SNOA) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $3.22 | -1.47 |
| Nov 3, 2025 | $3.78 | -1.72 |
| Oct 1, 2025 | $3.86 | -1.57 |
| Sep 2, 2025 | $4.71 | -1.92 |
| Aug 1, 2025 | $2.99 | -0.98 |
| Jul 1, 2025 | $2.95 | -0.97 |
| Jun 2, 2025 | $3.41 | -0.87 |
| May 1, 2025 | $3.54 | -0.90 |
| Apr 1, 2025 | $2.17 | -0.55 |
| Mar 3, 2025 | $2.12 | -0.54 |
| Feb 3, 2025 | $2.58 | -0.66 |
| Jan 2, 2025 | $2.68 | -0.55 |
Sonoma Pharmaceuticals (SNOA) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -1.28 | -22.89% |
| 2025 | -1.66 | +201.82% |
| 2024 | -0.55 | +358.33% |
| 2023 | -0.12 | -78.57% |
| 2022 | -0.56 | -67.63% |
| 2021 | -1.73 | — |
FAQs About Sonoma Pharmaceuticals (SNOA) P/E ratio
The latest P/E ratio of Sonoma Pharmaceuticals (SNOA) is -1.28, as of Mar 10, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Sonoma Pharmaceuticals’s last 12-month average P/E ratio is -1.29, compared to its current P/E ratio of -1.28. This reflects a decrease of -0.78%.
Sonoma Pharmaceuticals’s current P/E ratio of -1.28 is lower than its last 12-month average P/E of -1.29. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Sonoma Pharmaceuticals’s average P/E ratio over the last 3 years is -0.71. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Sonoma Pharmaceuticals’s average P/E ratio over the last 5 years is -1.18. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.